In Vitro: STING agonist-23 (10 μM; 3 h or 5 h) increases the level of phosphorylated STING, TBK1 and IRF3 following 3-h incubation, increases the level of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15 following 5-h incubation, and CCL-5, in THP-1 cells.
In Vivo: STING agonist-23 adjuvant (20?μg STING agonist-23 and 5 μg RBD-Fc per mouse; im; 3 times at 14-day intervals) induces strong antibody immune response induced by the SARS-CoV-2 RBD-Fc protein in mice model.